QUESTIONS MODERN EPILEPTOLOGY

G. N. Avakyan

QUESTIONS MODERN EPILEPTOLOGY

G. N. Avakyan

Full Text:

Abstract

Recent epidemiological studies in 16 regions of the Russian Federation showed that seizures in patients with epilepsy missing only 14.93% of patients. Less than 5% of patients receiving "new" anti-epileptic drugs (AEDs). In many cases, drugs are administered in doses lower than therapeutic. Hence the need to optimize the treatment, research new technologies and AEDs to treat drug-resistant epilepsy.

Keywords

epidemiological studies, antiepileptic drugs, drug-resistant epilepsy,

About the Author

G. N. Avakyan

Pirogov Russian National Research Medical University, Moscow
Russian Federation

Avakyan Gagik Norairovich – MD, Honored Scientist of Russia, Professor of Neurology, Neurosurgery and Medical Genetics.

Address: ul. Ostrovityanova 1, Moscow, Russia, 117997.

References

1. Avakyan G.N., Voronina T.A., Khromykh E.A. Epilepsy. Pathogenesis. Pathogenetic therapy. Manual for physicians [Epilepsii. Patogenez. Patogeneticheskaya terapiya. Posobie dlya vrachei (In Russian)]. Moscow. 2007; 148 p.

2. Avakyan G.N., Badalyan O.L., Nerobokova L.N., Voronina T.A. The possibility of using a combination of carbamazepine and mexidol adolescents with partial epilepsy. Epilepsy and Clinical Neurophysiology: Materials of the II East European Conference [Vozmozhnosti ispol'zovaniya kombinatsii karbamazepina i meksidola u podrostkov s partsial'noi epilepsiei. Epilepsiya i klinicheskaya neirofiziologiya: Materialy II Vostochno-Evropeiskoi konferentsii (In Russian)]. Gurzuf. 2000; 189-190.

3. Avakyan G.N. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2014; 4: 46-49.

4. Dokukina T.V., Golubeva T.S., Matveichuk I.V., Makhrov M.V., Loseva V.M., Krupen'kina E.V., Marchuk S.A. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2014; 7 (2) : 33-37.

5. Dokukina T.V., Golubeva T.S., Matveichuk I.V., Makhrov M.V., Loseva V.M., Krupen'kina E.V., Marchuk S.A. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2014; 2: 29-33.

6. Karlov V.A. Epilepsy in children and adults, women and men, children and adult women and men [Epilepsiya u detei i vzroslykh, zhenshchin i muzhchin detei i vzroslykh zhenshchin i muzhchin (In Russian)]. Moscow. 2010; 720p.

7. Kritskaya Yu.A., Shnaider N.A., Shirshov Yu.A. Epilepsiya i paroksizmal'nye sostoyaniya / Epilepsy and paroxysmal conditions. 2012; 1: 23-28.

8. Mukhin A.Yu., Petrukhin A.S., Mironov M.B. Epileptic syndromes. Diagnostics and therapy. 2008; 223 p.

9. European Chemicals Bureau; IUCLID Dataset for Sodium Metabisulfite (7681-57-4). p. 29.

10. Kale R. The treatment gap. Epilepsia. 2002; 43 (6): 31-33.

11. Forsgren L., Beghi E., Oun A., Sillanpaa M. The epidemiology of epilepsy in Europe a systematic review. Eur J Neurol. 2005 Apr; 12 (4): 245-53.

12. Guekht A., Hauser W.A., Milchakova L., Churillin Y., Shpak A., Gusev E. The epidemiology of epilepsy in the Russian Federation. Epilepsy Res. 2010 Dec; 92 (2-3): 209-18.

13. Hauser W.F. The descriptive epidemiology of epilepsy. Epilepsy: translational, clinical and social aspects. Moscow. 2013; 83-117.

14. Knodel L.C. Current Issues in Drug Toxicity; Potential health hazards of sulfites. Toxic Subst. Mech. 1997; 16 (3): 309-311.

15. Lewis R.J.Sr. (ed) Sax’s Dangerous Properties of Industrial Materials. 11th Edition. Wiley-lnterscience. NJ. 2004; p. 3261.

16. Papazian R. Sulfites: Safe for most, dangerous for some. FDA Consumer Magazine. 1996; 30 (10).

17. Wolf P. Praxisbuch Epilepsien. Diagnostik, Behandlung, Rehabilitation – Kohlhammer, Stuttgart. 2003; 394 p.

18. World Healt Organization. International Classification of Functioning Disability and Healt. 2001.

Supplementary files

For citation: Avakyan G.N. QUESTIONS MODERN EPILEPTOLOGY. Epilepsia and paroxyzmal conditions. 2015;7(4):16-21.

Refbacks

There are currently no refbacks.

ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)

Username
Password